3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Lung Neoplasms
2
Recurrence
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Gallbladder Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Edema
1
Adenocarcinoma
1
Interventions
Dexamethasone
8
Oxycodone
6
Epoetin Alfa
5
Propofol
4
Palonosetron
4
Meropenem
4
Zoledronic Acid
3
Vancomycin
3
Sevoflurane
3
Ondansetron
3
Naloxone
3
Everolimus
3
Ciprofloxacin
3
Cholecalciferol
3
Ceftazidime
3
Cefepime
3
Calcium Dobesilate
3
Bevacizumab
3
Aspirin
3
Aprepitant
3
peginterferon alfa-2a
2
edoxaban
2
apixaban
2
apatinib
2
Vitamin B 12
2
Vincristine
2
Tobacco Use Cessation Devices
2
Teicoplanin
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasms
×
Desflurane
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled